The registry platform, which specializes in preventing duplicate enrollment and protocol violations, will utilize the fresh capital to bolster its infrastructure and geographic reach. While the company maintains its current branding and commitments to data integrity, the influx of resources aims to deepen its impact on sponsors, research sites, and clinical trial participants. The company’s core technology remains a critical safeguard against the risks of study failure and compromised research quality.
In section Releases
Verified Clinical Trials secures WindRose investment and names new CEO
Boca Raton-based Verified Clinical Trials has entered a strategic partnership with WindRose Health Investors, marking a significant expansion phase for the registry platform. As part of this transition, industry veteran Howard Miller steps in as Chief Executive Officer to lead the firm’s next stage of global growth.
Howard Miller arrives with over three decades of experience in the life sciences sector, including leadership tenures at Envision Pharma Group and Two Labs. Co-founders Dr. Mitchell Efros and Kerri Weingard will transition into new strategic roles; Efros becomes President, focusing on client relationships, while Weingard assumes the position of Chief of Strategic Operations to oversee scaling efforts. WindRose partner CJ Burnes noted that the firm’s investment targets the company’s ability to reduce downstream clinical risks and improve safety standards across the pharmaceutical services landscape.
Comments (0)
No comments yet. Be the first!